3 results on atopic dermatitis
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
The objective of this phase III study is to evaluate the efficacy and safety of Tozorakimab according to 300 mg every 8 weeks (Q8W) and 300 mg every 4 weeks (Q4W) dosing regimens administered in adult participants with symptomatic COPD and a history…
* To evaluate the effects of topically applied erythromycin and clindamycin in patients with facial AV* To explore skin and faecal microbiota in patients with AV;* To evaluate the effects of topically applied erythromycin and clindamycin on skin and…